Roux-en-Y Gastric Bypass Improved Insulin Resistance via Alteration of the Human Gut Microbiome and Alleviation of Endotoxemia

Biomed Res Int. 2021 Jul 12:2021:5554991. doi: 10.1155/2021/5554991. eCollection 2021.

Abstract

Background: Obesity is a main contributing factor for the development of glucose intolerance and type 2 diabetes mellitus (T2D). Roux-en-Y gastric bypass (RYGB) is believed to be one of the most effective treatments to reduce body weight and improve glucose metabolism. In this study, we sought to explore the underlying mechanisms of weight reduction and insulin resistance improvement after RYGB.

Methods: This was a prospective observational study using consecutive samples of 14 obese subjects undergoing bariatric surgery. Main assessments were serum indexes (blood metabolites, glucose-lipid regulating hormones, trimethylamine-N-oxide (TMAO), and lipopolysaccharide-binding protein (LBP), fecal short-chain fatty acids (SCFAs), and gut microbiota. Correlation analysis of the factors changed by RYGB was used to indicate the potential mechanism by which surgery improves insulin resistance.

Results: The subjects showed significant improvement on indices of obesity and insulin resistance and a correlated change of gut microbiota components at 1 month, 3 months, and 6 months post-RYGB operation. In particular, the abundance of a counterobese strain, Akkemansia muciniphila, had gradually increased with the postoperative time. Moreover, these changes were negatively correlated to serum levels of LBP and positively correlated to serum TMAO and fecal SCFAs.

Conclusions: Our findings uncovered links between intestinal microbiota alterations, circulating endotoxemia, and insulin resistance. This suggests that the underlying mechanism of protection of the intestine by RYGB in obesity may be through changing the gut microbiota.

MeSH terms

  • Acute-Phase Proteins / metabolism
  • Carrier Proteins / metabolism
  • Down-Regulation
  • Endotoxemia / microbiology*
  • Endotoxemia / surgery*
  • Gastric Bypass*
  • Gastrointestinal Microbiome*
  • Humans
  • Insulin Resistance*
  • Membrane Glycoproteins / metabolism
  • Metabolome
  • Methylamines / metabolism
  • Obesity / microbiology
  • Obesity / surgery

Substances

  • Acute-Phase Proteins
  • Carrier Proteins
  • Membrane Glycoproteins
  • Methylamines
  • lipopolysaccharide-binding protein
  • trimethyloxamine